8 completed, 2 recruiting, 1 active not recruiting. 11 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 8, Recruiting 2, Active not recruiting 1 |
| Phase 2 | 8 | Completed 5, Recruiting 2, Active not recruiting 1 |
Follow Granuloma: new trials by email Literature Review of Granuloma trials Research Report on Granuloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare AC-1101 - Granuloma Annulare | Phase 1 | Completed | TWi Biotechnology, Inc. | 13 | 2022-10-03 | 2024-10-15 |
| Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors Brigatinib - Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 65 | 2022-08-18 | 2025-12-05 |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 75 | 2020-03-12 | 2026-09-25 |
| Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare Tofacitinib 5 mg twice daily - Cutaneous Sarcoidosis, Granuloma Annulare | Phase 1 | Completed | Yale University | 15 | 2019-04-11 | 2021-07-14 |
| Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo - Pulmonary Sarcoidosis | Phase 1 / Phase 2 | Completed | aTyr Pharma, Inc. | 37 | 2019-01-29 | 2023-07-18 |
| Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Ceritinib - ALK-activated Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 83 | 2013-08-28 | 2020-06-09 |
| Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Hematopoietic stem cell transplantation - Sickle Cell Disease, Thalassemia | Phase 1 / Phase 2 | Completed | Children's Hospital Los Angeles | 25 | 2008-08-01 | 2016-06-23 |
| Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Mepolizumab - Churg Strauss Syndrome | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 10 | 2007-09-01 | 2017-03-22 |
| Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix UVB Irradiation - Keloid, Scleroderma, Localized | Phase 1 / Phase 2 | Completed | University of Michigan | 33 | 2002-08-01 | 2015-05-01 |
| Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Mepolizumab - Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 24 | 2001-12-01 | 2020-07-29 |
Churg-Strauss Syndrome (3) · Granuloma Annulare (3) · Granuloma, Plasma Cell (3) · Lymphoma, Large-Cell, Anaplastic (3) · Lymphoproliferative Disorders (2) · Acne Keloid (1) · Anemia (1) · Anemia, Dyserythropoietic, Congenital (1) · Anemia, Sickle Cell (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Chediak-Higashi Syndrome (1) · Cicatrix (1) · Congenital amegakaryocytic thrombocytopenia (1) · Eosinophilic Esophagitis (1)
Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Lymphatic Diseases (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Skin and Connective Tissue Diseases (7) · Lymphoproliferative Disorders (6) · Skin Diseases (6) · Connective Tissue Diseases (5) · Immunoproliferative Disorders (5) · Autoimmune Diseases (3) · Cardiovascular Diseases (3) · Collagen Diseases (3) · Lymphoma, Non-Hodgkin (3)
mepolizumab (2) · Capsules (1) · Hematopoietic Stem Cell Transplantation (1) · Suspensions (1) · brigatinib (1) · ceritinib (1) · repotrectinib (1) · tofacitinib (1)
Alpine Immune Sciences, Inc. (1) · Brigham and Women's Hospital (1) · Children's Hospital Los Angeles (1) · Children's Hospital Medical Center, Cincinnati (1) · Novartis Pharmaceuticals (1) · Princess Maxima Center for Pediatric Oncology (1) · TWi Biotechnology, Inc. (1) · Turning Point Therapeutics, Inc. (1) · University of Michigan (1) · Yale University (1) · aTyr Pharma, Inc. (1)
United States (10) · Australia (3) · France (3) · South Korea (3) · Canada (2) · Italy (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Denmark (1) · Germany (1) · Puerto Rico (1) · Singapore (1) · Taiwan (1)
Gennyne Walker (1) · Hisham Abdel-Azim, MD (1) · John J Voorhees, MD (1) · Marc E. Rothenberg, MD (1) · Michael Wechsler, MD (1) · Michel Zwaan, Prof (1) · William Damsky, M.D., Ph.D. (1) · William Damsky, MD, PhD (1)
PMID 30697903, PMID 33317858, PMID 34780709, PMID 34814185, PMID 35668129, PMID 36356657, PMID 37854715
2023 (1)